文献速递头颈与中枢神经肿瘤

手术腔内注射CpG寡核苷酸治疗新诊断胶质母细胞瘤:一项II期多中心随机研究

Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study.
PubMed 文献 · Eur J Cancer · 2017-01-28

这项多中心单盲随机II期试验纳入81例新诊断胶质母细胞瘤患者,在大范围手术切除后于手术腔周围局部随机给予CpG-ODN,随后按标准治疗接受放疗和替莫唑胺。CpG-ODN组2年总生存率为31%,标准治疗组为26%;中位无进展生存期分别为9个月和8.5个月,两组不良事件发生率相似,但CpG-ODN组发热和术后血肿更常见。作者结论认为,局部免疫治疗虽耐受良好,但未改善新诊断胶质母细胞瘤患者的生存。

要点

  • CpG-ODN组2年总生存率31%,标准治疗组26%。
  • CpG-ODN组中位无进展生存期9个月,标准治疗组8.5个月。
  • 两组不良事件发生率相似,CpG-ODN组发热和术后血肿更常见。

核心结论

  • 局部注射CpG-ODN联合标准治疗虽耐受良好,但未改善新诊断胶质母细胞瘤患者的生存。

研究设计与样本

  • 多中心单盲随机II期试验,81例新诊断胶质母细胞瘤患者在大范围手术切除后随机接受CpG-ODN联合标准治疗(39例)或标准治疗(42例)。
  • 主要终点为2年生存率,次要终点为无进展生存期和耐受性。

主要发现

  • CpG-ODN组2年总生存率为31%(19%;49%),标准治疗组为26%(16%;44%)。
  • CpG-ODN组中位无进展生存期为9个月,标准治疗组为8.5个月。
  • 两组不良事件发生率相似,但CpG-ODN组发热和术后血肿更频繁。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunostimulating oligodeoxynucleotides containing unmethylated cytosine-guanosine motifs (CpG-ODN) have shown a promising efficacy in several cancer models when injected locally. A previous phase II study of CpG-ODN in patients with recurrent glioblastoma (GBM) has suggested some activity and has shown a limited toxicity. This multicentre single-blinded randomised phase II trial was designed to study the efficacy of a local treatment by CpG-ODN in patients with de novo glioblastomas. PATIENTS AND METHODS: Patients with a newly diagnosed glioblastoma underwent large surgical resection and CpG-ODN was randomly administrated locally around the surgical cavity. The patients were then treated according to standard of care (SOC) with radiotherapy and temozolomide. The primary objective was 2-year survival. Secondary outcomes were progression free survival (PFS), and tolerance. RESULTS: Eighty-one (81) patients were randomly assigned to receive CpG-ODN plus SOC (39 patients) or SOC (42 patients). The 2-year overall survival was 31% (19%; 49%) in the CpG-ODN arm and 26% (16%; 44%) in the SOC arm. The median PFS was 9 months in the CpG-ODN arm and 8.5 months in the SOC arm. The incidence of adverse events was similar in both arms; although fever and post-operative haematoma were more frequent in the CpG-ODN arm. CONCLUSIONS: Local immunotherapy with CpG-ODN injected into the surgical cavity after tumour removal and followed by SOC, although well tolerated, does not improve survival of patients with newly diagnosed GBM.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ursu R, Carpentier A, Metellus P, et al. Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study. Eur J Cancer. 2017. PMID: 28142059. doi:10.1016/j.ejca.2016.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。